<DOC>
	<DOCNO>NCT02218437</DOCNO>
	<brief_summary>Mesenchymal Stem Cells ( MSC ) non Hematopoietic Stem Cells ( HSC ) adult bone marrow take part bone marrow microenvironment . The response rate early treatment Children 's SAA application combine anti-thymocyte globulin ( ATG ) ( 40-50 day ATG treatment ) associate long-term effect . The injection Umbilical Cord Derived Mesenchymal Stem Cells combine ATG improve efficacy child SAA .</brief_summary>
	<brief_title>Treatment Protocol Child SAA With Injection Mesenchymal Stem Cells（Umbilical Cord Derived）</brief_title>
	<detailed_description>1 . Mesenchymal Stem Cells prepare vitro separation , screening , culture healthy human umbilical cord tissue ; The `` injection mesenchymal stem cell ( umbilical ) manufacture verification regulation `` also formulate . 2 . The start dose Umbilical Cord Derived MSC 0.5-1.0 * 106 cell /kg , base previous human study ; And maximum tolerate dose 1 * 107 cell /kg 3 . The response complete remission rate , relapse rate injection Umbilical Cord Derived Mesenchymal Stem Cells ( combine ATG ) Child SAA determine .</detailed_description>
	<criteria>NonSevere Aplastic Anemia ( NSAA ) atients Severe Aplastic Anemia ( SAA ) patient</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Mesenchymal Stem Cells ( MSC )</keyword>
	<keyword>Umbilical Cord</keyword>
	<keyword>thymocyte globulin ( ATG )</keyword>
	<keyword>Severe Aplastic Anemia ( SAA )</keyword>
</DOC>